Olivia Newton-John Cancer Wellness & Research Centre

Prospective phase I study of nivolumab to promote graft‐versus‐tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation

Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune reconstitution, tumour antigen downregulation or T‐cell exhaustion. This prospective...

An Exploratory Study of ABT-806, a Tumor-Specific Anti-EGFR Antibody, in Subjects with Recurrent or Metastatic Head and Neck and Other Squamous Cell Carcinomas

Introduction: Despite their benefit, current anti-EGFR therapies are limited by narrow efficacy profiles due to dose-limiting toxicities. This phase 2 open-label study evaluated the efficacy and safety of ABT-806, an EGFR-targeting antibody that is tumor specific, in patients wit...

Identification of immunodominant ERV peptides critical for anti-metastatic immunity in a model of TNBC

Abstract The integration of immunotherapy into neoadjuvant treatment for triple-negative breast cancer (TNBC) has improved outcomes in some patients. Pre-clinical investigation of immunotherapy resistance in the aggressive 4T1 TNBC model has been hampered by a lack of known tumou...

Novel chimeric PD-L1::PD-L2 fusion and immune evasion in lymphoma

We report a novel in-frame CD274::PDCD1LG2 fusion in primary mediastinal B-cell lymphoma. Functional studies using expression constructs and CRISPR-engineered lymphoma cells confirmed formation of a PD-L1::PD-L2 chimeric protein and marked upregulation of PD-L1 surface expression...